EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Azithromycin for Preventing Bronchopulmonary Dysplasia in Extremely Preterm Infants: A Cohort Study

Yali Zeng, Zhifeng Huang, Yanqiong Wang, Binchun Lin, Depeng Zhao, Chuanzhong Yang, Xueyu Chen

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.27384 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Yali Zeng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, the First School of Medicine, Southern Medical University, Shenzhen, Chi…. Hauptthemen laut MEDLINE: Azithromycin, Bronchopulmonary Dysplasia, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This study is supported by National Natural Science Foundation of China (82101803 to XC and 82371707 to CY), Sanming Project of Medicine in Shenzhen (SZSM20221….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To test the effect of azithromycin in reducing bronchopulmonary dysplasia (BPD) risk in extremely preterm infants (EPI) without pulmonary infection. Study Design A retrospective cohort study was performed in EPI in a tertiary unit from September 2018 to September 2022. Since only Ureaplasma species positive infants were treated with azithromycin, we included infants without Ureaplasma species (no azithromycin treatment) and those diagnosed with Ureaplasma species colonization (azithromycin treatment) in the study, while infants with Ureaplasma species pneumonia were excluded. The primary outcome was grade II + BPD, defined as BPD of grade II or higher according to the updated NICHD criteria (2018). Multiple logistic regression analysis was used to identify the independent association between grade II + BPD and azithromycin treatment.

Results

A total of 237 EPIs were included in the current study, of which 202 infants were classified as no azithromycin treatment ( Ureaplasma species negative) and 35 infants were classified as azithromycin treatment ( Ureaplasma species colonization). Clinical characteristics were similar between groups. Infants treated with azithromycin had a significantly lower rate of grade II + BPD (8.6% vs. 31.2%, p = 0.006), and shorter duration of invasive ventilation (0 vs. 3 days, p = 0.045) compared to untreated ones. After adjusting for confounders, azithromycin treatment was significantly associated with reduced risk of grade II + BPD in the whole cohort (odd ratio [OR] 0.211, 95% CI: 0.056, 0.786, p = 0.020], and infants absent of other pulmonary infection (OR 0.115, 95% CI: 0.014, 0.979, p = 0.048).

Conclusion

Azithromycin is associated with a reduced risk of grade II + BPD in EPIs, likely due to its anti‐inflammatory effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzithromycinBronchopulmonary DysplasiaAnti-Bacterial AgentsHumansRetrospective StudiesFemaleMaleInfant, NewbornInfant, Extremely PrematureUreaplasmaCohort StudiesUreaplasma Infections

Stichwörter der Autor:innen

Ureaplasmainflammationlungnewborn

Substanzen

AzithromycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, the First School of Medicine, Southern Medical University, Shenzhen, China.
  • Department of Reproductive Medicine, Shenzhen maternity and child healthcare hospital, the First School of Medicine, Southern Medical University, Shenzhen, China.
  • Shenzhen Key Laboratory of Maternal and Child Health and Diseases, Shenzhen, China.

Förderung

  • This study is supported by National Natural Science Foundation of China (82101803 to XC and 82371707 to CY), Sanming Project of Medicine in Shenzhen (SZSM20221…

Zitieren

APA

Zeng, Y., Huang, Z., Wang, Y., Lin, B., Zhao, D., Yang, C., & Chen, X. (2025). Azithromycin for Preventing Bronchopulmonary Dysplasia in Extremely Preterm Infants: A Cohort Study. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27384

Vancouver

Zeng Y, Huang Z, Wang Y, Lin B, Zhao D, Yang C, et al. Azithromycin for Preventing Bronchopulmonary Dysplasia in Extremely Preterm Infants: A Cohort Study. Pediatric Pulmonology. 2025. doi:10.1002/ppul.27384

BibTeX
@article{Zeng2025,
  author = {Zeng, Yali and Huang, Zhifeng and Wang, Yanqiong and Lin, Binchun and Zhao, Depeng and Yang, Chuanzhong and Chen, Xueyu},
  title = {Azithromycin for Preventing Bronchopulmonary Dysplasia in Extremely Preterm Infants: A Cohort Study},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.27384}
}
Kostenlos starten →